Abstract
We polled infectious disease specialists about cryptococcal antigen screening for patients initiating HIV antiretroviral therapy. Of 215 respondents, 33% reported typically obtaining screening for patients with CD4 counts <200 cells/mm(3) and 63% for counts <100 CD4 cells/mm(3). Uncertainty about cryptococcal antigen screening benefits and recommendations suggests opportunities for education and increased screening.